Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of VEGF...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Cao*, Liangxian, Weetall, Marla, Trotta, Christopher, Cintron, Katherine, Ma, Jiyuan, Kim, Min Jung, Furia, Bansri, Romfo, Charles, Graci, Jason D., Li, Wencheng, Du, Joshua, Sheedy, Josephine, Hedrick, Jean, Risher, Nicole, Yeh, Shirley, Qi, Hongyan, Arasu, Tamil, Hwang, Seongwoo, Lennox, William, Kong, Ronald, Petruska, Janet, Moon, Young-Choon, Babiak, John, Davis, Thomas W., Jacobson, Allan, Almstead, Neil G., Branstrom, Art, Colacino, Joseph M., Peltz, Stuart W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6318026/
https://ncbi.nlm.nih.gov/pubmed/30352802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0863
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados